SSR-161421

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameSSR-161421
Drug Alias NameSSR-161421
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A3 receptor antagonists
TargetsAdenosine A3 receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi-Synthelabo
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiSanofi-Synthelabo
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A
Related LinksN/A